Jim Cramer - Mad Money Prometheus Biosciences RXDX-Q BUY Dec 09, 2022

They make drugs to treat inflammatory bowel diseases, a big market. Last Wednesday they announced strong phase 2 trial data for a leading IBD drug. Shares soared 166% on Wednesday. This drug will mae RXDX a major pharma.

Jim Cramer - Mad Money

Unknown

Unlock Rating

$110.200

Stock price when the opinion was issued

biotechnology pharmaceutical

It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

Get Signals Create your Watchlist

Most Recent Experts

Paul MacDonald

Harvest Portfolios Group

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

Jamie Murray

Murray Wealth Group

Stockchase Insights

5i Research

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : hello@stockchase.com.

Jim Cramer - Mad Money Prometheus Biosciences RXDX-Q BUY Dec 09, 2022

Latest Buy Signals

Today's Top Picks

Popular Articles

Latest Sell Signals